Posted by Michael Wonder on 16 Nov 2020
Swissmedic begins rolling review of Moderna’s mRNA vaccine against COVID-19 (mRNA-1273)
13 November 2020 - Moderna completed enrolment of its Phase 3 COVE study of mRNA-1273 on October 22.
Moderna today announced that Swissmedic has started a rolling review of mRNA-1273, the Company’s vaccine candidate against COVID-19.
This announcement follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in adults (ages 18-55 years) and older adults (ages 56-70 and 71+) published in the New England Journal of Medicine.
